XLON
0OO9
Market cap25bUSD
Oct 21, Last price
41.23EUR
Name
Fresenius SE & Co KGaA
Chart & Performance
P/E
49.30
P/S
1.06
EPS
0.84
Div Yield, %
—
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-9.22%
Revenues
21.83b
-2.09%
Net income
471m
P
CFO
2.45b
-45.09%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||